Abstract #1135
Nitroxoline induces apoptosis and slows glioma growth in vivo
Jelena Lazovic 1 , Lea Guo 1 , Jonathan Nakashima 2 , and Whitney Pope 3
1
Radiology, University of California, Los
Angeles, California, United States,
2
Molecular
and Medical Pharmacology, University of California, Los
Angeles, California, United States,
3
University
of California, Los Angeles, California, United States
Chemotherapeutic potential of FDA approved small
molecule nitroxoline was evaluated in preclinical
Pten/Kras glioma mouse model. The glioma volume before
and after nitroxoline therapy was measured using
T2-weighted MR images. Apparent diffusion coefficient
and T2-values were quantified in order to determine if
they can be used to predict treatment response. A
significant reduction in glioma growth at 7 and 14 days
was accompanied with significant increase in ADC values,
while there was no change in T2-values. Histological
examination and TUNEL staining revealed significantly
more TUNEL-labeled cells in nitroxoline treated mice,
implicating nitroxoline is potent at inducing apoptosis
in this model.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
